Yuling Luo
Known title: Chief Executive OfficerCIK: 0002126941
Associated companies
Transaction History
| ALMR | ▼ Sell | Other | 1,386,746 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 364,268 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 1,864,065 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 1,864,065 | — | 4/20/2026 | View on chart |
| ALMR | ▲ Buy | Grant | 76,509 | $0 | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 1,224,152 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 1,224,152 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 1,224,152 | — | 4/20/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Alamar Biosciences Sets Q3 2026 Earnings Release Date
Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.
Alamar Biosciences Sets Q3 2026 Earnings Release Date. Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.